Neuroprotection and neurodegenerative disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
White, 1999, Basic research update: Evidence for neuroprotection with Topiramate
Leist, 1998, Apoptosis, excitotoxicity and neuropathology, Exp Cell Res, 239, 183, 10.1006/excr.1997.4026
Ellison, 2000, Neurodegenerative disorders, 26.1, 33.11
Ellison, 2000, Dementias, 31.1, 31.34
Nicotera, 1999, Excitotoxins in neuronal apoptosis and necrosis, J Cerebral Blood Flow & Metab, 19, 583, 10.1097/00004647-199906000-00001
Montal, 1998, Mitochondria, glutamate neurotoxicity and the death cascade, Biochim et Biophys Acta, 1366, 113, 10.1016/S0005-2728(98)00124-8
Martin, 1998, Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis, Brain Res Bull, 46, 281, 10.1016/S0361-9230(98)00024-0
Olney, 1969, Glutamate induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion, J Neuropathol Exp Neurol, 28, 455, 10.1097/00005072-196907000-00007
Brown, 1996, Neuropathology and pathogenesis of mitochondrial diseases, J Inher Metab Dis, 19, 553, 10.1007/BF01799116
Lipton, 1998, Neuroprotective versus neurodestructive effects of NO-related species, Biofactors, 8, 33, 10.1002/biof.5520080107
Ludolph, A, C, Meyer, T and Riepe, M, W. The role of excitotoxicityin ALS – what is the evidence?J Neurol 2000; 247(): I7–I16.
Arias, 1998, Glutamic acid and Alzheimer's disease, Neurobiology, 6, 33
Beal, 1996, Mitochondria, free radicals and neurodegeneration, Curr Opin Neurobiol, 6, 661, 10.1016/S0959-4388(96)80100-0
Nichols, 1998, Neuronal excitotoxicity: the role of mitochondria, Biofactors, 8, 287, 10.1002/biof.5520080317
Simpson, 1998, Role of mitochondrial Ca2+ regulation in neuronal and glial cell signalling, Brain Res Rev, 26, 72, 10.1016/S0165-0173(97)00056-8
Scheffer, 1995, Autosomal dominant nocturnal frontal lobe epilepsy, A distinctive clinical disorder. Brain, 118, 61
White, 1999, Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs, Epilepsia, 40, S2, 10.1111/j.1528-1157.1999.tb00913.x
Perucca, 1997, A pharmacological and clinical review on Topiramate, a new antiepileptic drug, Pharmacol Res, 35, 241, 10.1006/phrs.1997.0124
Hanaya, 1998, Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro, Brain Res, 789, 274, 10.1016/S0006-8993(98)00116-4
Yang, 1998, Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization, Brain Res, 804, 169, 10.1016/S0006-8993(98)00410-7
Macdonald, 1999, Cellular actions of antiepileptic drugs, 123
Walker, 1999, Lamotrigine, 331
Meldrum, 1993, Pharmacology and mechanism of action of lamotrigine, 5
Shaw, 1997, Glutamate, excitotoxicity and amyotrophic lateral sclerosis, J Neurol, 244, S3, 10.1007/BF03160574
Robberecht, 2000, Oxidative stress in amyotrophic lateral sclerosis, J Neurol, 247, I1, 10.1007/s004150050551
Ellison, 2000, Motor Neuron Disorders, 27.1, 27.10
Ellison, 2000, Parkinson's Disease, 28.1, 28.16
Jenner, 1996, Oxidative stress and the pathogenesis of Parkinson's disease, Neurology, 47, S161, 10.1212/WNL.47.6_Suppl_3.161S
Langston, 1996, The aetiology of Parkinson's disease with emphasis on the MPTP story, Neurology, 47, S153, 10.1212/WNL.47.6_Suppl_3.153S
Tatton, 1996, Modulation of gene expression rather than monoamine oxidase inhibition: (−)-deprenyl-related compounds in controlling neurodegeneration, Neurology, 47, S171, 10.1212/WNL.47.6_Suppl_3.171S
Rinne, 1984, Brain neurotransmitters and neuropeptides in Parkinson's disease, Acta Physiol Pharmacol Latinoam, 34, 287
Olanow, 1996, Selegiline: current perspectives on issues related to neuroprotection and mortality, Neurology, 47, S210, 10.1212/WNL.47.6_Suppl_3.210S
Burkhardt, 2000, Riluzole protects dopamine neurons against oxidative stress and impairment of cellular energy supply, Neurology, 54, A52
Ellison, 2000, Multiple Sclerosis, 19.1, 19.12
Lassmann, 1998, Neuropathology in multiple sclerosis: new concepts, Multiple Sclerosis, 4, 93, 10.1177/135245859800400301
Trapp, 1998, Axonal transection in the lesions of multiple sclerosis, N Engl J Med, 338, 278, 10.1056/NEJM199801293380502
Cohen, 2000, Intense immune ablative therapy with autologous hematopoietic stem cell rescue for progressive multiple sclerosis: a pilot safety study, Neurology, 54, A59
Whartenby, 2000, An open label trial of combination MS therapy using IFN β1a and oral methotrexate 20mg weekly, Neurology, 54, A24
Ellison, 2000, Alzheimer's Disease, 31.1, 31.34
Lipton, 1996, Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischaemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species, Brain Pathol, 6, 507, 10.1111/j.1750-3639.1996.tb00879.x
Mattson, 1998, Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease, Int J Devl Neurosci, 16, 737, 10.1016/S0736-5748(98)00082-3
Blass, 1996, Pathophysiology of the Alzheimer syndrome, 17
Giulian, 1998, A strategy for identifying immunosuppressive therapies for Alzheimer Disease, Alzheimer Disease & Associated Disorders, 12, S7
Engert, 1999, Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches, Semin Hematol, 36, 282